Vical Incorporated Release: Allovectin(R) Demonstrates Synergistic Efficacy With Anti-CTLA-4 Antibody in Melanoma Animal Model

BETHESDA, Md., Sept. 22, 2011 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today encouraging animal data demonstrating a synergistic (more than additive) improvement in efficacy using a combination of the company’s Allovectin® immunotherapy with an anti-CTLA-4 antibody.